Workflow
海特生物: 股票交易异常波动的公告

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days (July 21, 2025, July 22, 2025, and July 23, 2025) [1] - The board of directors conducted a verification regarding the stock's abnormal fluctuation and confirmed that there are no undisclosed significant information or major matters under planning that could impact the stock price [1][1] - The board also confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's rules, and previous disclosures do not require correction or supplementation [1][1] Group 2 - The company reported a net profit attributable to shareholders of -69.3487 million yuan for the year 2024 [2]